Aole Zheng

Aole Zheng

Auto-generated profile, based on publicly available information

Aole Zheng

Department of Clinical Pharmacy and Pharmacy Administration, School of Pharmaceutical Sciences Fudan University Shanghai China

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 February 2025 in CPT: Pharmacometrics & Systems Pharmacology
Verified
Journal Article
Open access
Dongsheng YangDongsheng Yang
Dongsheng Yang
JLJian Li
Jian Li
WMWen Yao Mak
Wen Yao Mak
AZAole Zheng
Aole Zheng
XZXiao Zhu
Xiao Zhu
XXXiaoqiang Xiang
Xiaoqiang Xiang
Physiologically based pharmacokinetic (PBPK) modeling, a cornerstone of model‐informed drug development and model‐informed precision dosing, simulates drug disposition in the human body by integrating physiological, biochemical, and physicochemical parameters. While PBPK modeling has advanced globally since the 1970s, China's adoption of this technology has followed a distinctive path, characterized by accelerated growth over the past 2 decades. This review provides a comprehensive analysis of China's contributions to PBPK modeling, addressing knowledge gaps in publication trends, application domains, and platform preferences. A systematic literature search yielded 266 original PBPK research articles from PubMed up to August 08, 2024. The analysis revealed that drug disposition and drug–drug interaction studies constitute the largest proportion of PBPK analyses in China. Chinese universities and hospitals emerge as the leading contributors to PBPK research among institutions in China. Although established commercial PBPK platform such as GastroPlus and Simcyp remain popular within the Chinese pharmaceutical industry, open‐source platforms like PK‐Sim are gaining significant traction in PBPK applications across China. This review underscores the transformative potential of PBPK modeling in drug development within China, offering valuable insights into future directions and challenges in the field.

30 March 2024 in European Journal of Pharmaceutical Sciences
Verified
Journal Article
Open access
AZAole Zheng
Aole Zheng
Dongsheng YangDongsheng Yang
Dongsheng Yang
CPChunyang Pan
Chunyang Pan
QHQingfeng He
Qingfeng He
XZXiao Zhu
Xiao Zhu
PJPeiying Ji
Peiying Ji
Lenvatinib's efficacy as a frontline targeted therapy for radioactive iodine-refractory thyroid carcinoma and advanced hepatocellular carcinoma owes to its inhibition of multiple tyrosine kinases. However, as a CYP3A4 substrate, lenvatinib bears susceptibility to pharmacokinetic modulation by co-administered agents. Schisantherin A (STA) and schisandrin A (SIA) - bioactive lignans abundant in the traditional Chinese medicinal Wuzhi Capsule - act as CYP3A4 inhibitors, engendering the potential for drug-drug interactions (DDIs) with lenvatinib. To explore potential DDIs between lenvatinib and STA/SIA, we developed a physiologically-based pharmacokinetic (PBPK) model for lenvatinib and used it to construct a DDI model for lenvatinib and STA/SIA. The model was validated with clinical trial data and used to predict changes in lenvatinib exposure with combined treatment. Following single-dose administration, the predicted area under the plasma concentration-time curve (AUC) and maximum plasma concentrations (Cmax) of lenvatinib increased 1.00- to 1.03-fold and 1.00- to 1.01-fold, respectively, in the presence of STA/SIA. Simulations of multiple-dose regimens revealed slightly greater interactions, with lenvatinib AUC0-t and Cmax increasing up to 1.09-fold and 1.02-fold, respectively. Our study developed the first PBPK and DDI models for lenvatinib as a victim drug. STA and SIA slightly increased lenvatinib exposure in simulations, providing clinically valuable information on the safety of concurrent use. Given the minimal pharmacokinetic changes, STA/SIA are unlikely to interact with lenvatinib through pharmacokinetic alterations synergistically but rather may enhance efficacy through inherent anti-cancer efficacy of STA/ SIA.

21 December 2025 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Closed access
WMWen Yao Mak
Wen Yao Mak
MAMuyesaier Alifu
Muyesaier Alifu
AZAole Zheng
Aole Zheng
NJNing Jia
Ning Jia
QINGFENG HEQINGFENG HE
QINGFENG HE
XXXiaoqiang Xiang
Xiaoqiang Xiang

1 June 2026 in Pharmacoeconomics and Policy
Verified
Journal Article
Open access
AZAole Zheng
Aole Zheng
WMWen Yao Mak
Wen Yao Mak
XSXiaoping Shi
Xiaoping Shi
XZXinyue Zhang
Xinyue Zhang
JNJiaqi Ni
Jiaqi Ni
QINGFENG HEQINGFENG HE
QINGFENG HE